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Histiocytic Lymphoma in Renal Transplant Patients 
Receiving Cyclosporine 
J. T. Rosenthal, S. Iwatsuki, T. E. Starzl, R. J. Taylor, and T. R. Hakala 
THE higher incidence of cancer in immu-nosuppressed patients over. the gene.ral 
population has long been recogmzed. A high 
rcentage of these cancers have been called 
:;mphomas. The first clinical trial of cyclo-
lporine for renal transplantation re~or~ed by 
CaIne et al.I included almost a 10% inCIdence 
of lymphoma (3/3:): Concern was ~xpressed 
(or the ultimate utIlity of cyclosporme based 
on this experience. We now have experience in 
over 300 cases of cadaveric renal transplanta-
tion over a 3.5-year period. In this article we 
present the experience ~it~ f~mphomaK i~ 
these patients, documenting inCidence, chm-
cal presentation, treatment, and outcome fol-
luwing cadaveric renal transplantation. 
From December 1979 to September 1980, 
M patients underwent cadaveric renal trans-
plantation in Denver in the first trials with 
eycJosporine and steroid combination. The 
re~ults of that trial have been reported in 
detail by Starzl et al.2.3 From March 1981 to 
I Q!U an additional 244 patients have under-
Fone cadaveric renal transplantation in Pitts-
burgh, using the same immunosuppression 
regimen. The results of this experience have 
been reported.4•5 Immunosuppression con-
~i~ted of cyclosporine, 17.5 mg/kg/day, 
begun by mouth pretransplant and daily 
thereafter. Tapering occurred from 2 weeks to 
(, months posttransplant. The average cyclo-
sporine dose at 1 year posttransplant was 6 
mg/kg/day. Methylprednisolone, I g, was 
Itiven i.v. pretransplant. Prednisone was begun 
by mouth on day 1 posttransplant and tapered 
over 5 days to 20 mg/day. By I year, the 
average prednisone dose was 10 mg/day. 
Six patients of the 310 (1.9%) developed 
"lymphoma" during the course of these trial~K 
Two of these have been reported in detai1.2•6 
Four additional cases will be discussed here in 
addition to these two. The clinical features of 
the patients are shown in Table 1. These were 
5 males and 1 female; age ranged from 16 
years to 57 years. Five patients developed 
bowel lesions, which were manifested by per-
foration and peritonitis. One patient devel-
oped a painless neck swelling. The time of 
development of the lesion was 3-6 months 
posttransplant. The first patient from the 
Denver series was receiving 16 mg/kg/ day of 
cyclosporine at the time of development of 
lymphoma at 6 months posttransplant. The 
other 5 patients were receiving 6-11 mg/ 
kg/day cyclosporine 3-5 months posttrans-
plant at the time of development of lympho-
ma. Only one patient had been treated for 
rejection; this consisted of recycling of oral 
steroid to 200 mg/day, with a 5-day taper 
again to 20 mg/day. Three patients had oral 
herpes within 1-2 months of transplantation, 
while 2 patients had elevated serum creatinine 
indicative of cyclosporine nephrotoxicity. 
The five patients with bowel lesions under-
went resection of the affected segment and 
prompt reduction in the dose of cyclosporine .. 
Two of these patients received small doses of 
cytotoxic drugs before the lesions were ade-
quately characterized. One patient received 
small doses of acyclovir. The others had the 
cyclosporine dose reduced, but received no 
other treatment. The patient with the neck 
mass received local radiation, primarily 
because most of the lesion was necrotic and 
could not adequately be characterized. No 
systemic therapy was undertaken in this 
patient, except to lower the cyclosporine dose. 
Dose adjustment was in the range of 1-3 
mg/kg/day cyclosporine. 
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Dose 
Patient Age/Sex (mg/kg/Day) 
l.P. 25F 16 
S.C. 21M 10 
A.L. 49M 6 
P.L. 57M 8 
E.F. 30M 10 
L.S. 16M 8 
All 6 patients so treated are alive and well 3 
months to 4 years after treatment (Table 2). 
Two patients suffered irreversible rejection of 
the graft when immunosuppression was 
decreased. The other 4 patients have normal 
renal function. 
Interpretation of the histopathology in each 
case was histiocytic lymphoma. Four lesions 
were subsequently characterized as polyclonal 
B-cell masses by immunoperoxidase staining. 
The neck mass tissue was mostly necrotic, 
precluding characterization. The tumor mass 
from one patient showed no immunoglobulin. 
Most of the tissue resected from the bowel was 
necrotic also, so that EBNA was identified in 
only one tumor. This also prevented DNA 
hybridization studies for Epstein-Barr virus 
(EBV) genome. Serology to EBV disclosed 
evidence of primary infection in one patient 
(L.P.) previously reported2 and reinfection in 
another (E.F.), manifested by a threefold rise 
Table 2. Treatment and Outcome 
Patient Graft 
Patient Treatment Survival Survival 
L.P. Bowel resection Yes Yes 
Decrease cyclosporine 
S.C. Bowel resection Yes Yes 
Decrease cyclosporine 
A.L local radiation Yes Yes 
Decrease cyclosporine 
P.L. Bowel resection Yes Yes 
Decrease cyclosporine 
ChemoRx 
E.F. Bowel resection Yes No 
Decrease cyclosporine 
ChemoRx 
L.S. Bowel resection Yes No 
Decrease cyclosporine 
Site 
Bowel 
Bowel 
Neck 
Bowel. 
prostate 
Bowel 
Bowel 
Time 
After 
Transplant 
6 Months 
5 Months 
3 Months 
4 Months 
4 Months 
3 Months 
in antibody titer to viral capsid antigen (Table 
3). 
DISCUSSION 
Because of the high incidence of lymphoma 
in the early experience with cyclosporine, it 
was feared that the drug itself was more 
tumorogenic than conventional immunosup-
pression regimens and that its use would be 
severely limited by this fact. Two issues are of 
concern; one is the incidence, and the other is 
the clinical significance of these lesions. Over-
all incidence of lymphoma reported here is 
1.9%, considerably less than the feared 10% 
and comparable to the 2.5% reported by Bird7 
in cycIosporine-treated cases and comparable 
to the incidence reported in cadaveric renal 
transplantation under conventional immuno-
suppression.8 Evidence that the development 
of these lesions is related to the general level of 
immunosuppression comes from the higher 
incidence of tumors reported from cardiac 
transplantation,9 where immunosuppression 
may be maintained at a higher level out of 
necessity. 
The role of Epstein-Barr virus in the devel-
opment of these lymphomas has been well 
described.1O Epstein-Barr virus is implicated 
directly or indirectly in 3 of the 6 patients 
reported here. The majority of these lesions 
Table 3. Immunologic Studies 
loP. Polyclonal B cell Primary EBV infection 
S.C. No immunoglobulin EBNA positive 
A.l. 
P.l. Polyclonal B cell 
E.F. Polycional B cell Reactivation EBV infection 
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have been found to be polyclonal, as opposed 
to monoclonality of killing lymphoma. 
Whether or not they can be distinguished by 
morphology is not clear. 11 All the material in 
our six cases was interpreted as histiocytic 
lymphoma prior to immunologic examination. 
When polyclonality is determined, the term 
Iymphoproliferative disorder is more appro-
priate, or perhaps. fOseudo~ymp~omaI as 
described by IwatsukI. The Issue IS of more 
than academic interest, since there is great 
enthusiasm for the use of cytotoxic drugs 
when the clinical diagnosis of histiocytic lym-
phoma appears on ~he chart. mrevio~slyI the~e 
was a high mortality, two of three 10 CaIne s 
first group, 1 and five of six in the cases 
reported by Hanto. 10 If this is a virally induced 
B-cell proliferation, maintenance of immuno-
suppression and the use of cytotoxic drugs 
would be counterproductive. Iwatsuki treated 
three patients by reduction of immunosup-
pression only, with good outcome in all three 
patients.12 In our six patients, only two 
received small doses of cytotoxic drugs before 
the exact nature of their lesions could be 
discerned. In all six cases, significant reduc-
tions in immune suppression were carried out 
immediately. Prompt resolution occurred in 
all patients so treated. The effectiveness of 
this maneuver was vividly documented in one 
patient who required repeat laparotomy for 
persistent GI bleeding. This was found to be 
suture line bleeding and was corrected by 
repeat resection. At the time of this repeat 
resection, I month following his original oper-
ation, large bowel lesions that had been seen 
at the first operation and left in place were 
entirely resolved. The question of transforma-
tion from polyclonal to monoclonal cannot be 
answered from the clinical data presently 
available. It has been suggested that mono-
clonal lesions in transplant patients are killing 
cancer and associated with development of 
chromosomal abnormalities in the B cells so 
transformed by virus. \3 
CONCLUSION 
Incidence of lymphoma using cyclosporine 
and steroid is no different than in transplanta-
tion under conventional immunosuppression. 
Most of these lesions are more appropriately 
called Iymphoproliferative disorders despite 
their histologic appearance. When the masses 
are polyclonal, prompt reduction in immuno-
suppression should result in excellent survival. 
The role for additional antiviral agents for 
treatment is unclear, but played no role here. 
Cytotoxic drugs should be avoided. 
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